CA - Pfizer Opts To Move Forward With Once-Daily Danuglipron - Don't Hold Your Breath

2024-07-11 14:19:51 ET

Summary

• Pfizer Inc. announced today that it planned to continue development of its GLP-1 agonist weight loss drug danuglipron as a once-daily oral pill.
• The drug met efficacy endpoints in a Phase 2 study last year as a twice daily pill, but side effects caused a high level of patient withdrawals, undermining the results.
• The company says testing of the once-daily version reveals no evidence of liver damage - but it is a long way adrift in the GLP-1 space.
• Lilly and Novo Nordisk's Zepbound and Wegovy are set to dominate a market potentially worth >$150bn, but there are several other contenders of note in clinical studies.
• Danuglipron feels like a back-marker in a crowded field - Pfizer may be better off focusing on the >$70bn worth of M&A deals it has made and the >$45bn of new revenue it has forecast from these sources.

Investment Overview

Back in December last year, I shared a note on Pfizer Inc. ( PFE ), the beleaguered “Big Pharma” company, entitled “Disastrous 2023 Hits New Low With Weight Loss Drug Failure.”...

For further details see: